Acetoxy-20-tert-butyldimethylsilyloxy-pregn-5-ene-7-one | 1201435-48-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Acetoxy-20-tert-butyldimethylsilyloxy-pregn-5-ene-7-one
• 英文别名: 3-Acetoxy-20-tert-butyldimethylsilyloxy-pregn-5-en-7-one；[(8S,9S,10R,13S,14S,17S)-17-[1-[tert-butyl(dimethyl)silyl]oxyethyl]-10,13-dimethyl-7-oxo-1,2,3,4,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-yl] acetate
• CAS: 1201435-48-4
• 化学式: C₂₉H₄₈O₄Si
• 分子量: 488.783
• InChiKey: OXWLRENSEIRZOX-LPFMLCHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.09
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Acetoxy-20-tert-butyldimethylsilyloxy-pregn-5-ene-7-one 、 、 甲基氯化镁 在 ice 、 solution 、 氯化铵 、 乙酸乙酯 、 magnesium sulfate 、 Sodium sulfate-III 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以to yield the title compound (265.7 gm, 92.3% yield)的产率得到20-tert-butyldimethylsilyloxy-7-methyl-pregn-5-ene-3,7-diol
  参考文献：
  名称：

  4-aza-pregnane 5.alpha.-reductase isozyme 1 inhibitors

  摘要：

  式(I)的化合物，其中：R.sup.1选自氢和甲基组成的群；R.sup.2选自甲基和乙基组成的群；R.sup.3选自氢和甲基组成的群；C1-C2碳-碳键可以是单键或双键。这些化合物在治疗需要阻断5α-还原酶同工酶的病理情况方面很有用。##STR1##

  公开号：

  US05658922A1
• 作为产物：
  描述：

  3-Acetoxy-20-tert-butvldimethvlsilyloxy-pregn-5-ene 、 N-羟基邻苯二甲酰亚胺 在 过氧化苯甲酰 N-羟基邻苯二甲酰亚胺 、 过氧化苯甲酰 、 二氯甲烷 、 吡啶 、 乙酸酐 、 甲醇 、 ice 作用下， 以 丁酮 为溶剂， 反应 100.5h， 以to yield the title compound (110.6 gm, 32% yield)的产率得到Acetoxy-20-tert-butyldimethylsilyloxy-pregn-5-ene-7-one
  参考文献：
  名称：

  4-aza-pregnane 5.alpha.-reductase isozyme 1 inhibitors

  摘要：

  式(I)的化合物，其中：R.sup.1选自氢和甲基组成的群；R.sup.2选自甲基和乙基组成的群；R.sup.3选自氢和甲基组成的群；C1-C2碳-碳键可以是单键或双键。这些化合物在治疗需要阻断5α-还原酶同工酶的病理情况方面很有用。##STR1##

  公开号：

  US05658922A1

文献信息

• 17-alkyl-7-substituted-4-aza steroid derivatives as 5-.alpha.-reductase
  申请人：Merck & Co., Inc.

  公开号：US05763361A1

  公开（公告）日：1998-06-09

  The novel compounds of the present invention are those of structural formula I: ##STR1## or a pharmaceutically acceptable salt, or stereoisomer thereof, which are inhibitors of 5.alpha.-reductase, particularly 5.alpha.-reductase type 1. The compounds of formula I are useful in the systemic, including oral, or parenteral or topical treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia which includes female and male pattern baldness, female hirsutism, benign prostafic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as in the treatment of prostatitis. Methods of using the compounds of formula I for the treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as the treatment of prostatitis are provided, as well as pharmaceutical compositions for the compounds of formula I. The use of compounds of formula I in combination with other, active agents, for example with a 5.alpha.-reductase type 2 inhibitor such as finasteride or epristeride, or a potassium channel opener, such as minoxidil, or a retinoic acid or a derivative thereof is also taught, wherein such combinations would be useful in one or more of the above-mentioned methods of treatment or pharmaceutical compositions.

  本发明的新化合物为结构式I的化合物：##STR1##或其药学上可接受的盐或立体异构体，它们是5α-还原酶的抑制剂，特别是5α-还原酶类型1。式I的化合物在系统性治疗，包括口服、或经皮或局部治疗过多雄激素症状，如痤疮、皮脂溢出、雄激素性脱发，包括女性和男性型脱发、女性多毛症、良性前列腺增生症的预防和治疗以及前列腺癌的治疗中有用，还可用于前列腺炎的治疗。本发明提供了使用式I的化合物治疗过多雄激素症状，如痤疮、皮脂溢出、雄激素性脱发、男性型脱发、女性多毛症、良性前列腺增生症、前列腺癌的预防和治疗以及前列腺炎的方法，以及式I的化合物的药物组合物。还教授了与其他活性剂的化合物I的使用，例如与5α-还原酶类型2抑制剂（如非那雄胺或依普利司特）或钾通道开放剂（如米诺地尔）或视黄酸或其衍生物的组合，其中这些组合物在上述一种或多种治疗方法或药物组合物中有用。
• Methods and compositions for treating preterm labor
  申请人：Merck & Co., Inc.

  公开号：US05872126A1

  公开（公告）日：1999-02-16

  The present invention provides for a method of treating preterm labor in a subject in need of such treatment comprising administration of a therapeutically effective amount of an inhibitor of 5.alpha.-reductase type 1 to the subject. The present invention further provides for a method of preventing premature labor in a subject susceptible thereto comprising administration of a labor-preventive amount of an inhibitor of 5.alpha.-reductase type 1 to the subject. Further, the present invention also relates to a method of reducing the risk of premature labor in a subject at risk therefor. The present invention also provides for a method for stopping labor preparatory (i.e., prior) to Cesarean delivery in a subject in need of such treatment comprising administration of a therapeutically effective amount of an inhibitor of 5.alpha.-reductase type 1 to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating pre-term labor and for stopping labor preparatory to Cesarean delivery.

  本发明提供了一种治疗需要此类治疗的早产的方法，包括向受试者施用5α-还原酶类型1的抑制剂的治疗有效量。本发明还提供了一种预防易感受早产的受试者的早产的方法，包括向受试者施用5α-还原酶类型1的抑制剂的预防性剂量。此外，本发明还涉及一种减少易感受早产的受试者的早产风险的方法。本发明还提供了一种在需要此类治疗的受试者中停止分娩准备（即在剖腹产前）的方法，包括向受试者施用5α-还原酶类型1的治疗有效量的抑制剂。此外，本发明还提供了在本发明方法中有用的组合物，以及用于治疗早产和在剖腹产前停止分娩准备的药物的制造方法。